Class information for:
Level 1: CHIMERIC ANTIGEN RECEPTOR//ADOPTIVE CELL THERAPY//CHIMERIC IMMUNE RECEPTOR

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
4142 1764 50.9 93%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
151 22214 IMMUNOTHERAPY//DENDRITIC CELLS//CANCER IMMUNOLOGY IMMUNOTHERAPY

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CHIMERIC ANTIGEN RECEPTOR Author keyword 127 67% 7% 116
2 ADOPTIVE CELL THERAPY Author keyword 29 42% 3% 54
3 CHIMERIC IMMUNE RECEPTOR Author keyword 27 92% 1% 11
4 SURG BRANCH Address 26 16% 9% 156
5 CLIN EXPT IMMUNOTHER Y GRP Address 26 100% 1% 11
6 ADOPTIVE T CELL THERAPY Author keyword 22 39% 3% 45
7 CHIMERIC ANTIGEN RECEPTORS Author keyword 20 58% 1% 23
8 TCR GENE TRANSFER Author keyword 18 83% 1% 10
9 CHIMERIC T CELL RECEPTOR Author keyword 17 75% 1% 12
10 UNIT 907 Address 15 82% 1% 9

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CHIMERIC ANTIGEN RECEPTOR 127 67% 7% 116 Search CHIMERIC+ANTIGEN+RECEPTOR Search CHIMERIC+ANTIGEN+RECEPTOR
2 ADOPTIVE CELL THERAPY 29 42% 3% 54 Search ADOPTIVE+CELL+THERAPY Search ADOPTIVE+CELL+THERAPY
3 CHIMERIC IMMUNE RECEPTOR 27 92% 1% 11 Search CHIMERIC+IMMUNE+RECEPTOR Search CHIMERIC+IMMUNE+RECEPTOR
4 ADOPTIVE T CELL THERAPY 22 39% 3% 45 Search ADOPTIVE+T+CELL+THERAPY Search ADOPTIVE+T+CELL+THERAPY
5 CHIMERIC ANTIGEN RECEPTORS 20 58% 1% 23 Search CHIMERIC+ANTIGEN+RECEPTORS Search CHIMERIC+ANTIGEN+RECEPTORS
6 TCR GENE TRANSFER 18 83% 1% 10 Search TCR+GENE+TRANSFER Search TCR+GENE+TRANSFER
7 CHIMERIC T CELL RECEPTOR 17 75% 1% 12 Search CHIMERIC+T+CELL+RECEPTOR Search CHIMERIC+T+CELL+RECEPTOR
8 ADOPTIVE IMMUNOTHERAPY 15 15% 5% 93 Search ADOPTIVE+IMMUNOTHERAPY Search ADOPTIVE+IMMUNOTHERAPY
9 TCR GENE THERAPY 15 73% 1% 11 Search TCR+GENE+THERAPY Search TCR+GENE+THERAPY
10 ADOPTIVE CELL TRANSFER 12 38% 1% 26 Search ADOPTIVE+CELL+TRANSFER Search ADOPTIVE+CELL+TRANSFER

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CANCER REGRESSION 196 59% 13% 223
2 CHIMERIC ANTIGEN RECEPTOR 144 64% 8% 141
3 IN VIVO PERSISTENCE 100 71% 5% 80
4 TRANSFER THERAPY 68 48% 6% 105
5 ADOPTIVE IMMUNOTHERAPY 60 16% 20% 346
6 ADVERSE EVENT 53 61% 3% 57
7 ENHANCED ANTITUMOR ACTIVITY 51 56% 4% 63
8 CHIMERIC SINGLE CHAIN 42 94% 1% 15
9 TCR GENE TRANSFER 36 63% 2% 36
10 SUPERIOR ANTITUMOR IMMUNITY 32 68% 2% 28

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Antibody-modified T cells: CARs take the front seat for hematologic malignancies 2014 72 69 74%
Adoptive immunotherapy for cancer: harnessing the T cell response 2012 315 149 46%
Adoptive cell transfer as personalized immunotherapy for human cancer 2015 13 89 69%
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies 2015 11 161 66%
Neoantigens in cancer immunotherapy 2015 15 49 43%
Chimeric Antigen Receptor Therapy for Cancer 2014 38 77 71%
Adoptive cell therapy for the treatment of patients with metastatic melanoma 2009 281 39 64%
Adoptive cell transfer: a clinical path to effective cancer immunotherapy 2008 547 70 43%
The Basic Principles of Chimeric Antigen Receptor Design 2013 84 87 71%
The promise and potential pitfalls of chimeric antigen receptors 2009 152 118 85%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SURG BRANCH 26 16% 8.8% 156
2 CLIN EXPT IMMUNOTHER Y GRP 26 100% 0.6% 11
3 UNIT 907 15 82% 0.5% 9
4 CELL GENE THER Y 14 10% 7.5% 133
5 EXPT TUMOR IMMUNOL 14 65% 0.7% 13
6 RIC MATILDE TETTAMANTI 12 86% 0.3% 6
7 THER EUT IMMUNOMOL 9 52% 0.7% 12
8 TUMORGENET 8 60% 0.5% 9
9 UNIT CLIN TUMOR IMMUNOL 7 67% 0.3% 6
10 MANCHESTER HEALTHCARE SCI 6 80% 0.2% 4

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000175965 CCDC134//TUMOR IMMUN TOLERANCE SECT//ANTIGEN SPECIFIC CTL FUNCTION
2 0.0000133835 CYTOKINE INDUCED KILLER CELLS//CIK CELLS//CYTOKINE INDUCED KILLER CELL
3 0.0000117671 CMV SPECIFIC T CELLS//ONCOHEMATOL GRP//CYTOMEGALOVIRUS SPECIFIC T CELLS
4 0.0000100152 2A PEPTIDE//FMDV 2A//2A
5 0.0000095968 CAROLINA CANC NANOTECHNOL EXCELLENCE//ARTIFICIAL ANTIGEN PRESENTING CELL//SLOAN KETTERING CANC
6 0.0000091580 CANCER TESTIS ANTIGEN//CANCER TESTIS ANTIGENS//NY ESO 1
7 0.0000086240 PEPTIDE MHC//PEPTIDE MAJOR HISTOCOMPATIBILITY COMPLEX//PROT CRYSTALLOG UNIT
8 0.0000081927 MINOR HISTOCOMPATIBILITY ANTIGENS//MINOR HISTOCOMPATIBILITY ANTIGEN//HA 1
9 0.0000080299 TUMOR INFILTRATING LYMPHOCYTES//ADOPTIVE IMMUNOTHERAPY//AUTOLYMPHOCYTE THERAPY
10 0.0000071188 FOXP3//TUMOR INFILTRATING LYMPHOCYTES//INTEGRAT CANC IMMUNOL